Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT1013 injection in hemodialysis patients with secondary hyperparathyroidism (phase IIb, single-arm)
CTR20241598Phase 2Active
- Sponsor
- Shaanxi Micot Technology Co., Ltd.
- Start
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of MT1013 in secondary hyperparathyroidism (SHPT), sponsored by Shaanxi Micot Technology Co., Ltd.. Started Jun 2024; status: active.
02
Drugs
MT1013
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on CTR20241598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241598.